Chapters

Transcript

Video

Based on clinical data and FDA approvals, why do NCCN guidelines for NSCLC recommend erlotinib and gefitinib as first-line systemic therapy in patients with sensitizing EGFR mutations?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professor Byoung Chul Cho, MD, PhD

Professor Byoung Chul Cho, MD, PhD

Yonsei Cancer Center
Yonsei University College of Medicine J
JE-UK Laboratory of Molecular Cancer Therapeutics
Seoul, Korea